ONXEO: up sharply after obtaining a patent reinforcing the protection of its composs


Largest increase in the SRD market with a gain of 8.57% 0.57 euro, Onxeo announced yesterday that it received a notification of intention to grant the European Patent Office (EPO) a patent to strengthen the protection in Europe of composs from its platform platON. This patent will provide a protection term extending until 2031 which could be extended until 2036 via the supplementary protection certificate (PPC) system.This new patent strengthens the patent portfolio around AsiDNA, a first-in-class inhibitor of DNA Damage Response (DDR). It protects AsiDNA as well as apparent compounds, as such and for their use in therapy, particularly for the treatment of cancers, alone or in combination with other agents such as radiotherapy, chemotherapy or other agents damaging the skin. Tumor DNA.

Copyright 2019 AOF
All rights of reproduction and representation reserved (Legal notice)

Source link


Please enter your comment!
Please enter your name here

2 × four =